The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA TransferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, Farah Eaton et al.|Diabetes|2022Cited by 14
The antipsychotic dopamine 2 receptor antagonist diphenylbutylpiperidines improve glycemia in experimental obesity by inhibiting succinyl-CoA:3-ketoacid CoA transferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, Amanda A. Greenwell et al.|Unknown|2022Cited by 1
The antipsychotic dopamine 2 receptor antagonist diphenylbutylpiperidines improve glycemia in experimental obesity by inhibiting succinyl-CoA:3-ketoacid CoA transferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, Amanda A. Greenwell et al.|Unknown|2022Cited by 0
The antipsychotic dopamine 2 receptor antagonist diphenylbutylpiperidines improve glycemia in experimental obesity by inhibiting succinyl-CoA:3-ketoacid CoA transferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, J. N. Mark Glover et al.|Unknown|2022Cited by 0